JPRN-UMIN000012134已完成未知
A multicenter, randomized, comparative trial on the effect of febuxostat in preventing cerebral and cardiorenovascular events in patients with hyperuricemia - Febuxostat for cerebral and caRdiorenovascular events prEvEntion stuDy (FREED)
FREED Study Group0 个研究点目标入组 1,000 人开始时间: 2013年10月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
ric acid level lowering by febuxostat provides clinical benefit for prevention of cerebral, cardiovascular, and renal events in elderly patients with hyperuricemia. Febuxostat may be expected to prevent the development and progression of chronic kidney disease. However, excessive lowering treatment by febuxostat may be avoided.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with gouty tophus, or patients with subjective symptoms of gouty arthritis within 1 year prior to enrollment (2)Patients with a previous history of hypersensitivity to febuxostat or allopurinol (3)Patients with malignant tumors (4)Patients with serious kidney disease, Acute kidney disease, nephrotic syndrome, dialysis patients, kidney transplant patients, eGFR < 30 mL/min/1.73 m2, etc. (5)Patients with a previous history of acute coronary syndrome or stroke within 3 months prior to enrollment (cerebral hemorrhage, cerebral infarction, or subarachnoid hemorrhage) (6)Patients with a >= 50% increase in serum creatinine within 3 months prior to enrollment (7)Patients with severe hypertension characterized by systolic blood pressure >= 180 mmHg or diastolic blood pressure >= 110 mmHg within 3 months prior to enrollment (8)Patients with AST or ALT 2 or more times the upper limit of normal within 3 months prior to enrollment (9)Patients on any of the following medications at enrollment Mercaptopurine hydrate, azathioprine, vidarabine, or didanosine (10)Patients who receive any of the following medications for the treatment of hyperuricemia within 1 month prior to enrollment Allopurinol, benzbromarone, probenecid, bucolome, topiroxostat, or febuxostat (11)Patients who start, modify the dose of, or discontinue any of the following medications within 1 month prior to enrollment Losartan, irbesartan, fenofibrate, thiazide diuretics, or loop diuretics (12)Patients on hormone replacement therapy with estrogen (estrogenic hormone products) (13)Patients who have participated in other clinical research (including trials) within 6 months prior to enrollment (non-interventional observational research not excluded) (14)Patients otherwise judged by the principal or sub-investigator to be unsuitable for the study
研究者
相似试验
Unknown
不适用
Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDyHyperuricemiaNCT01984749Freed Study Group1,000
已完成
3 期
Febuxostat Versus Allopurinol Control Trial in Subjects With GoutGoutNCT00102440Takeda760
已完成
2 期
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With GoutGoutNCT00174967Takeda153
Unknown
2 期
Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)Contrast-induced Acute Kidney InjuryContrast-induced NephropathyNCT03767322Instituto Nacional de Cardiologia Ignacio Chavez558
已完成
3 期
Efficacy and Safety of Oral Febuxostat in Participants With GoutGoutNCT00430248Takeda2,269